BioCentury
ARTICLE | Clinical News

Cidara discontinues CD101 topical for vulvovaginal candidiasis

February 21, 2017 11:40 PM UTC

Cidara Therapeutics Inc. (NASDAQ:CDTX) plummeted $4.50 (38%) to $7.20 on Tuesday after discontinuing development of CD101 topical to treat vulvovaginal candidiasis. Both gel and ointment formulations of the product led to lower clinical and mycological cure rates vs. oral fluconazole in the Phase II RADIANT trial to treat moderate to severe acute vulvovaginal candidiasis.

In the modified intent-to-treat (mITT) population (n=89), CD101 topical gel and ointment led to clinical cure rates at day 7 of 37.5% and 40%, respectively, vs. 47.4% for fluconazole. Clinical cure was defined as a score of zero points on the vaginal scoring system (VSS), which determines infection severity on a scale of zero to three points for each of six signs and symptoms for a maximum score of 18 points...

BCIQ Company Profiles

Cidara Therapeutics Inc.